FDA grants Priority Review and sets PDUFA target action date of November 26, 2021LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held, clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the U.S. Food and Drug ... Read More